AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03121157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-Component Technology Based Intervention
Description: The intervention group receives two sessions of computer-delivered MI via software programmed to target adherence to medications and text messaged adherence reminders between sessions. Sessions are provided by an avatar. The intervention engages the youth with the avatar's communication of empathy, optimism, and autonomy support. The intervention focuses the youth on adherence and relevant health behaviors with feedback on adherence, asthma symptoms, and tailored education. Participants are guided in the planning process through goal setting activities. The length of the intervention sessions are about 30 minutes each, with the total duration of the visit (assessment and intervention) lasting about 1.5 hours.
Study NCT03639701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymidine
Description: Mitochondrial DNA nucleotide precursors. Dose escalation: 130mg/kg/day x 14 days, 260 mg/kg/day x 14 days, and 400mg/kg/day as tolerated. Compounds are taken orally and divided into 3 doses daily.
Study NCT02782702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulism Toxin Treatment
Description: Injection of 50 UI of botulism toxin for treated zone
Study NCT02367755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol use during therapeutic hypothermia
Study NCT02367755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Lorazepam use during therapeutic hypothermia
Study NCT00441701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navarixin 1 mg
Description: Navarixin 1 mg capsules
Study NCT00441701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navarixin 10 mg
Description: Navarixin 10 mg capsules
Study NCT00441701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match navarixin
Description: Placebo to navarixin capsules
Study NCT00441701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match navarixin
Description: Placebo to navarixin capsules
Study NCT02547142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Palliative Care
Description: Metastatic esophageal cancer patients that receive early palliative care along with standard oncological care
Study NCT01311765 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Duration of antibiotic therapy limited to 8 days
Description: Initiation of adequate empiric antibiotics for postoperative peritonitis within 24 hours after surgery and up to 8 days. At randomisation performed on day 8, the patients assigned to the 8-day group (short-course group) stop their treatment
Study NCT00441701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: Salbutamol/albuterol - 2 puffs of salbutamol/albuterol approximately every 4 hours as needed for dyspnea relief
Study NCT00441701 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue medication
Description: Salbutamol/albuterol - 2 puffs of salbutamol/albuterol approximately every 4 hours as needed for dyspnea relief
Study NCT02236845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lacrima Medical Device and sham comparator
Study NCT02236845 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Lacrima Medical Device and sham comparator
Study NCT06315647 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DGT vs TPS vs Precut and fistulotomy in Difficult CBD cannulation
Description: comparison between different technique in difficult CBD cannulation
Study NCT01126879 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: genistein
Description: Given orally
Study NCT01126879 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT01126879 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Radical prostatectomy for treatment of prostate cancer
Study NCT01126879 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Radical prostatectomy for treatment of prostate cancer
Study NCT03861429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Me & My Wishes
Description: Me \& My Wishes videos communicate residents' preferences via personalized video recorded conversations. Me \& My Wishes are videos of nursing home residents talking about their preferences for care, and include four sections: About Me, Preferences for Today, Preferences for Medical Intervention and End of Life, and Afterthoughts.
Study NCT03861429 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Me & My Wishes
Description: Me \& My Wishes videos communicate residents' preferences via personalized video recorded conversations. Me \& My Wishes are videos of nursing home residents talking about their preferences for care, and include four sections: About Me, Preferences for Today, Preferences for Medical Intervention and End of Life, and Afterthoughts.
Study NCT00582192 — intervention group
Intervention type: OTHER
Intervention: Consult visit
Description: Your appointment with your doctor will be audio taped. The research team will listen to the tape(s) and type them up. The team will then look for patterns in the discussions between patients and doctors. They will use this information to see if the discussions can be improved.
Study NCT01523028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soluble Coffee
Description: Amounts of chlorogenic acids will be normalized to body weight (3.1 mg CA / kg BW). Coffee will be reconstituted in 200 mL hot water and consumed 3 times in a row (min 1-week interval), alone or with a breakfast:~* 200 mL coffee or~* 200 mL coffee + 2 bread rolls + honey~* 200 mL coffee + 1 bread roll + peanut butter
Study NCT03865862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The athletes will perform an intervention of 4 weeks, with two weekly sessions, in which the intervention will be performed during the training, with these sessions lasting 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 repetitions of squats in a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a rest of 15 seconds between series. This intervention will be performed adding 50% of his OR as external load during the first two weeks, 55% of his MR during the third week, and 60% of his MR in the fourth week of the intervention. During the exercise you can help the physiotherapist who will accompany you to perform the concentric phase without load.
Study NCT03865862 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Intervention of 4 weeks, with two weekly sessions, in which the intervention will be carried out during the training, these sessions having a duration of 10 minutes. During the performance of the intervention, they will perform 3 sets of 15 squat repetitions on a 25º inclined plane, performing the eccentric phase of the squat in a time of 4 seconds, the concentric phase in 3 seconds, and a 15-second rest between series. The subjects of this group will perform the protocol using only their own weight as a load.
Study NCT00411463 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal and Social Rhythm Therapy (IPSRT-BPII)
Description: IPSRT is comprised of three components: psychoeducation, social rhythm therapy, and standard IPT as developed for unipolar depression.~Psychoeducation focuses on a) the illness and its consequences, b) treatment options and associated side effects, and c) prodromal symptoms/detection of early warning symptoms.
Study NCT00411463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seroquel
Description: Subjects will be started at 100 mg/day titrated to a maximum of 800 mg /day~Day 1-BID doses totaling 100 mg/day, increased to 400 mg/day on Day 4 in increments of up to 100 mg/day in BID divided doses, by Day 6 begin titration up to a maximum dose of 800 mg/day in increments no greater than 200 mg/day.~This titration schedule may be adjusted based on the subject's response and ability to tolerate Seroquel.~Subjects who are unable to tolerate the study medications, or for whom the study medications are an inappropriate clinical choice, will be treated openly by a clinic physician according to the standard of care guidelines designated by the American Psychiatric Association (2002) for the treatment of bipolar disorder.
Study NCT00936195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz-Tenofovir-Emtricitabine
Description: Atripla (R) : Efavirenz 600 mg - Tenofovir 300 mg - Emtricitabine 200 mg; Dosage : 1 pill/day
Study NCT00936195 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine-Lamivudine-Lopinavir/Ritonavir
Description: Combivir (R) : Zidovudine 300 mg - Lamivudine 150 mg Dosage : 1 pill twice a day~Kaletra (R) or Aluvia (R) : Lopinavir 200 mg / Ritonavir 50 mg Dosage : 2 or 3 pills twice a day
Study NCT00692445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TC-5214 + citalopram
Description: TC-5214 (as TC-5214-23) will be provided as white, opaque, hard-gelatin capsules in strengths of 1, 2, and 4 mg.
Study NCT01304030 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empathy Training Modules
Description: The Empathy Training Modules utilize translational research in emotion expression basic science, physiology of emotions, decoding facial expressions and self-regulation skills as pertaining to management of medical and surgical patients.
Study NCT01304030 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Residency Training as usual
Description: Residents will receive their typical didactic and clinical education
Study NCT00314314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Insulin
Description: Intranasal spray; 40 IU qid; 8 weeks
Study NCT00314314 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diluent
Description: Intranasal spray; 8 weeks
Study NCT01113502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Oral formulation taken daily
Study NCT01144026 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TUTI-16 (0.2mg)
Description: Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.
Study NCT01144026 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TUTI-16 (1.0 mg)
Description: Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.
Study NCT03129854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: prostate cryotherapy
Description: prostate cryotherapy added to experimental group within 6 months of ADT
Study NCT00958581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: For TXA, the loading dose is 10mg/kg infused over 15 minutes, while the maintenance dose is 1/mg/kg hr.
Study NCT00958581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline of same volume as the intervention group will be given as the intervention group as a loading dose and maintenance dose.
Study NCT00692445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + citalopram
Description: Placebo will be provided with exactly the same shape, size and appearance. Subjects will take 2, 4, or 8 mg of study drug (or matching placebo), divided BID.
Study NCT00958581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epsilon aminocaproic acid
Description: For EACA, the loading dose is 100mg/kg infused over 15 minutes, while the maintenance dose is 10mg/kg hr.
Study NCT04289220 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD19 CAR-T Cells Injection
Description: Dosage form：injection Dosage:1-2.5x10\^6 cells/kg, 100ml/time, The CAR-T cells will be administered by i.v. injection over 20-30 minutes, Frequency: total one time
Study NCT04444167 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104
Description: Subjects will receive AK104 and lenvatinib until disease progression or for a maximum of 24 months
Study NCT04444167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Subjects will receive AK104 and lenvatinib until disease progression for a maximum of 24 months
Study NCT03590756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 16 weeks mango intake
Description: Participants will be provided fresh frozen Ataulfo mangoes.
Study NCT03590756 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 16 weeks mango intake
Description: Participants will be provided fresh frozen Ataulfo mangoes.
Study NCT03386201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Methylene blue
Description: Methylene blue fluorescence cholangiography during laparoscopic cholecystectomy
Study NCT00107250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1000 mg/m2 orally twice daily (total of 2000 mg/m2 per day) for the first 14 days of a 21 day cycle for a maximum of 6-8 cycles.
Study NCT00107250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC 6; IV; 30 minutes; Every 21 days for a maximum of 6-8 cycles
Study NCT00107250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given daily; orally with approximately 240 ml of water whilst in an upright position
Study NCT00107250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 200mg/m2; IV; 3 hours; Every 21 days for a maximum of 6-8 cycles
Study NCT01274182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GP2013
Description: 1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
Study NCT01274182 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MabThera
Description: 1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
Study NCT01274182 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituxan
Description: 1000 mg iv infusion on two separate occasions, two weeks apart (i.e. on Day 1 and on Day 15)
Study NCT02002026 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Uterine artery ligation
Description: Uterine artery ligation during cesarean section before delivery of the baby
Study NCT02002026 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uterine artery ligation
Description: Uterine artery ligation during cesarean section before delivery of the baby
Study NCT02200796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Meal
Description: High carbohydrate meal
Study NCT01265745 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline for Injection
Description: Equivalent amounts to subjects weight, once over 120 minutes
Study NCT02200796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Protein Meal
Description: Omelet with 15 g of protein
Study NCT02200796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate Protein Meal
Description: Omelet with 30 g of protein
Study NCT02200796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Meal
Description: Omelet with 45 g of protein
Study NCT01290406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEZ235
Study NCT01257841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leptin administration
Description: Leptin 0.05 mg/kg sc daily in divided doses (0800, 1400, 2000, and 0200h) for four days.
Study NCT01257841 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Fasting
Description: Complete fasting, save for water and multivitamin, for four days.
Study NCT01257841 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fasting
Description: Complete fasting, save for water and multivitamin, for four days.
Study NCT02718703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Glucose Monitoring System.
Description: In vitro diagnostic medical device
Study NCT01225328 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation/problem-solving (BA/PS)
Description: Six weekly telephone sessions to train participant in BA/PS procedures
Study NCT02386059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: received normal saline, intravenously
Study NCT02386059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 4 mg, intravenously, at the start of surgery
Study NCT02386059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 4 mg, intravenously, 15 minutes before the end of surgery.
Study NCT02386059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone + Ondansetron
Description: 4 mg dexamethasone, intravenously at the start of surgery and 4 mg ondansetron intravenously 15 minutes before the end of surgery.
Study NCT04190654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-6356
Description: Single oral dose of KW-6356
Study NCT02036281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Substance P-Saporin
Study NCT00418873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zotepine
Description: Oral
Study NCT03494166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Start with SMSH+TIPC
Description: See arm/group descriptions
Study NCT00418873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Oral
Study NCT03494166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Start with SMSH alone
Description: See arm/group descriptions
Study NCT00777374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patch
Description: epicutaneous application of allergen patch
Study NCT00777374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: epicutanoeus application of a placebo patch
Study NCT00952822 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)
Description: Subjects are randomized to receive an infusion of rAHF-PFM reconstituted in 2 mL sterile water for infusion (SWFI) followed (after a wash-out period) by rAHF-PFM reconstituted in 5 mL SWFI or in 5 mL then 2 mL SWFI(cross-over design). Each subject will receive 2 infusions.
Study NCT00952822 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)
Description: Subjects are randomized to receive an infusion of rAHF-PFM reconstituted in 2 mL sterile water for infusion (SWFI) followed (after a wash-out period) by rAHF-PFM reconstituted in 5 mL SWFI or in 5 mL then 2 mL SWFI(cross-over design). Each subject will receive 2 infusions.
Study NCT02463617 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: magnetic resonance imaging
Study NCT01265745 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MDX1303
Description: a sterile solution at a protein concentration of 25 mg/mL: 20 mM sodium citrate, 50 mM sodium chloride, 3.0% mannitol, 50 µM diethylenetriamine pentacetic acid and 0.06% polysorbate 80 at pH 6.5. A tubular, clear glass vial, filled with a 5 mL dose of colorless to pale yellow solution. The vial is sealed with a 20 mm stopper and white flip-off seal.
Study NCT01392924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245408
Description: Pharmaceutical form: tablet Route of administration: oral
Study NCT03428503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: 1000 mg of paracetamol (perfalgan 10mg/ml solutionBristol-Myers Squibb_UK) intravenous (IV) was given 100patients
Study NCT03428503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen
Description: Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
Study NCT04150744 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: take advantage of RFA to destroy hepatocellular carcinoma by high temperature
Study NCT04150744 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: radiofrequency ablation
Description: take advantage of RFA to destroy hepatocellular carcinoma by high temperature
Study NCT03750149 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeTracker
Description: Patients with various ophthalmologic diseases (ERM, glaucoma, AMD, diabetic retinopathy) will undergo reading analysis using the EyeTracker
Study NCT01521390 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK573719 62.5 mcg (one strip)
Description: GSK573719 62.5 mcg delivered by 1 strip configuration of novel dry powder inhaler
Study NCT01521390 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK573719 62.5 mcg(two strips)
Description: GSK573719 62.5 mcg delivered by 2 strip configuration of novel dry powder inhaler
Study NCT01521390 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK573719 125 mcg (one strip)
Description: GSK573719 125 mcg delivered by 1 strip configuration of novel dry powder inhaler
Study NCT01521390 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK573719 125 mcg(two strips)
Description: GSK573719 125 mcg delivered by 2 strip configuration of novel dry powder inhaler